28 unknown. 28 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Unknown 28 |
| Phase 2 | 8 | Unknown 8 |
Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Standard endocrine therapy plus Apatinib - HR+/HER2-breast Cancer | Phase 3 | Unknown | Fudan University | 916 | 2023-06-01 | 2023-06-05 |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab - C-staged Hepatocellular Carcinoma in BCLC Classification | Phase 3 | Unknown | Sun Yat-sen University | 140 | 2022-06-15 | 2022-06-16 |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell Camrelizumab, Apatinib - Esophageal Cancer | Phase 3 | Unknown | Feng Wang | 234 | 2021-12-05 | 2021-09-20 |
| Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy pablizumab combined with apatinib and neoadjuvant chemotherapy - Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2021-08-01 | 2021-07-20 |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride Injection - Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | Phase 3 | Unknown | RemeGen Co., Ltd. | 351 | 2021-03-24 | 2023-12-21 |
| Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. Camrelizumab combined with Apatinib, Etoposide and Cisplatin - Lung Neoplasm, Small Cell Lung Cancer | Phase 3 | Unknown | Fuzhou General Hospital | 45 | 2020-08-01 | 2021-02-08 |
| A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation Fluzoparib; Apatinib, Fluzoparib, Physician's choice chemotherapy - Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 474 | 2020-07-13 | 2020-08-10 |
| Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) Camrelizumab 200mg, Apatinib Mesylate 250mg, Pemetrexed disodium for injection - PD-L1 Positive Non-small Cell Lung Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 762 | 2020-06-15 | 2020-05-08 |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy Fluzoparib; Apatinib, Fluzoparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 690 | 2020-06-02 | 2022-04-25 |
| Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer Apatinib, Etoposide, Paclitaxel - Ovarian Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 280 | 2019-08-16 | 2019-10-08 |
| The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Apatinib, Capecitabine - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Unknown | Fudan University | 242 | 2019-03-22 | 2019-03-26 |
| Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer Apatinib, Irinotecan - Small Cell Lung Cancer | Phase 3 | Unknown | Beijing Chest Hospital | 90 | 2018-09-08 | 2018-08-29 |
| Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer Apatinib+Capecitabine, Apatinib - Gastric Cancer | Phase 3 | Unknown | Huazhong University of Science and Technology | 288 | 2018-01-16 | 2018-07-26 |
| XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma Apatinib, XELOX - Gastric Carcinoma | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 456 | 2017-12-20 | 2017-11-28 |
| Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Apatinib, paclitaxel, cisplatin - Breast Cancer | Phase 2 / Phase 3 | Unknown | Hebei Medical University Fourth Hospital | 200 | 2017-06-01 | 2021-07-09 |
| An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric Apatinib - Esophagus Cancer, Stage III, Esophageal Gastric Cardia Type Metaplasia | Phase 2 / Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2017-03-01 | 2017-09-18 |
| A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer cisplatin, etoposide, cisplatin, etoposide, apatinib - Progression Free Survival | Phase 3 | Unknown | Qingdao University | 120 | 2017-03-01 | 2017-04-04 |
| Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Apatinib Oral Tablet, Placebo Oral Tablet - Differentiated Thyroid Cancer | Phase 3 | Unknown | Peking Union Medical College Hospital | 118 | 2016-12-01 | 2023-04-12 |
| A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations Apatinib, Gefitinib, Placebo - EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors | Phase 3 | Unknown | Sun Yat-sen University | 246 | 2016-06-01 | 2016-07-07 |
Showing 20 of 28. Sign in to see all of them.
Stomach Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (4) · Esophageal Neoplasms (2) · Ovarian Neoplasms (2) · Small Cell Lung Carcinoma (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Digestive System Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Stomach Diseases (1)
Jiangsu HengRui Medicine Co., Ltd. (5) · Sun Yat-sen University (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Fudan University (2) · Hebei Medical University (2) · Anhui Provincial Hospital (1) · Beijing Chest Hospital (1) · Feng Wang (1) · Fuzhou General Hospital (1) · Hebei Medical University Fourth Hospital (1) · Huazhong University of Science and Technology (1) · Peking Union Medical College Hospital (1) · Qingdao University (1) · RemeGen Co., Ltd. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (20)
Feng Wang (1) · Han Liang, Master (1) · Hongyun Zhao (1) · Li Zhang, MD (1) · Liu Tianshu, doctor (1) · Pan Zhanyu, Master (1) · Xianglin Yuan, PhD,MD (1) · Xiong Chen (1) · Ying Zhou, MD (1) · Yunjiang Liu, MD.,PhD (1) · Zhanyu Pan, Master (1) · Zhuang Yu, MD, Ph. D (1)
PMID 31699150, PMID 32508029, PMID 33067126, PMID 33323401, PMID 34033974, PMID 34913959, PMID 35909569, PMID 39924483, PMID 41308673